Distinctive Proteins Discovery After Drug Combination Treatment In Triple Negative Breast Cancer By Ultra-high Throughput Antibody Microarray

Triple-negative breast cancer(TNBC)constitute nearly 20% of breast cancer,since the subtype of breast cancer go through noncanonical pathway to get proliferation signal from abnormal mutation,the method for specific anti-breast cancer drug will be useless,the overall survival and 5 year survival is less than normal breast cancer.The drugs combination are hold the future for anti-cancer treatment,as the combination strategy will not only enhance the efficacy by synergistic effect,but also decrease the toxic of each drug.Traditional anti-fungi drug itraconazole can crab the cancer growth through Hedgehog pathway.On the other side,as pan PI3 K inhibitor GDC-0941 could control various type of cancer.Through previous reading and early test,we find that combine this two medicines together could efficiently restrain triple-negative breast cancer cell line growth.But the different expression of proteins within two samples(with or without anti-cancer drug)was unknown,and there is limited technologies to investigate this problem at fast speed,low cost and high throughput.Our research developed an fast,low cost,and high throughput method depending on ultra-high throughput antibody microarray(contained 17,260 antibodies),which could detect proteomics change within two samples.In particular,after combining itraconazole and GDC-0941 we discovery a new differential protein for this two drugs mixture-eIF3 I,a protein that excluded from Hedgehog and PI3 K pathway.Furthermore,in vitro experiment clarify such result.In conclusion,depending on ultra-high throughput antibody microarray,our study established an time-saving,economical and highthroughput method to discovery a new target protein eIF3 I after itraconazole and GDC-0941 treatment in TNBC cell line.Moreover,this methods could be employed in other global proteomics comparison to find new targets or pathway changes.